Consistent, high-quality mRNAs are required to develop personalized mRNA therapeutics, such as patient-specific cancer vaccines or protein replacements for rare diseases.

In vitro transcribed (IVT) mRNA synthesis presents several key benefits, including simplified cell-free manufacturing, cell cycle-independent performance, and no risk of insertional mutagenesis.

GenScript offers custom IVT mRNA production via our expert RNA team based in Seattle, Washington. Our proprietary IVT RNA manufacturing workflow is both simple and versatile, with many customizable options.


100 bp – 20 kb sequences

<0.2mg to gram level

5' Cap Options


Cap1 (Co-Capped or enzymatic)

Cap2 (Co-Capped)


Poly(A) Tail Options

100A Tail (recommended)

Custom tail ≤ 120A

No Tail

Modified NTP options



5meC &  Ψ

Cy5-UTP or Thio-CTP


Popular off-the-shelf mRNA catalogs available now!

Try our catalog mRNA expressing reporter genes, Cas protein, or SB-100 transposase, all delivered in just 5 days! Learn More >>

One-Stop Solution for ALL Your mRNA Needs

GenScript’s solution to IVT mRNA manufacturing streamlines your workflow from gene synthesis to mRNA production. Our IVT mRNAs are optimized with our proprietary production platform, ensuring the quality and expression efficiency of your mRNA.

  • Codon optimization for protein expression offered every day for every gene
  • Codon optimization with >200 factors screened (patent)
  • 100 bp – 20 kb gene inserts
  • TAT as fast as 6 BDs to 14 BDs
  • Gene synthesis with Poly(A)-built-in vector
  • Ready to use linearized plasmid DNA for IVT
  • Vectors encoded stable Poly(A) tracts with variance of only +/- 5-10 nt
  • Customized RUO to preclinical grade mRNA service
  • Advanced purification (Oligo dT, dsRNA removal) and variety of QC options
Lipid Nanoparticles
  • Generic ionizable lipid formulation
  • Load 1-30mg, up to 10kb mRNA

Why GenScript

Integrated Production Process icon

Integrated Production Process

Service covering from gene to mRNA synthesis

Proprietary mRNA Vector

For optimized IVT production

Uniform Poly(A) tail

Enhances expression efficiency

Purification & QC

Advanced purification (Oligo dT, dsRNA removal) and QC analysis available
Experienced Team icon

Experienced Team with Optimized
Production Platform

Save your time & effort in designing and making mRNA
Customized or off-the-shelf mRNA icon

Customized / off-the-shelf mRNA

Variety of choices to fulfill your research needs


Quality Control and Specification

QC Item Test Method Specification RUO
Identification Appearance Visual Inspect Clear and free of foreign particles
RNA Length Capillary Electrophoresis Target ± 30%
RNA Length Agarose Gel Electrophoresis Expected size band detected
Poly A Length Enzyme digestion and CE Target ± 30%
RNA Content UV Absorbance Target ± 5%
PH pH meter Target ± 0.5
Buffer Specification Client Spec N/A
Purity A 260/280 Ratio UV Spec 1.70 ~ 2.30
Capping Efficiency LC-MS ≥ 90%
Size based purity Capillary Electrophoresis ≥75%
Impurity Total protein residue Nano Orange Assay ≤ 1%
Plasmid DNA Residue qPCR 0.05%
dsRNA Slot-blot 0.1%
Safety Endotoxin Semiquantitative < 10EU/mg
Endotoxin Quantitative < 10EU/mg
Bioburden Sdirect Inoculation No Growth after
48 hrs

Note: Additional QC and characterizations are offered with an extra charge upon request.

Comparison of different IVT RNA payload formats

Linear mRNA Self-Amplifying RNA Circular RNA
Structure Linear; Open 5’ and 3’ end
mRNA exonuclease degradation
Linear; Open 5’ and 3’ end
mRNA exonuclease degradation
Close loop; No free 5’ 3’ end
Eliminating mRNA exonuclease degradation
Ribosome recruiting 5’ Cap:
Initiates translation & stabilizes mRNA
5’ Cap:
Initiates translation & stabilizes mRNA
Internal Ribosome Entry Site (IRES) :
Initiates translation
  • Codon optimization for translation yield
  • Modified nucleosides, eg. M1Ψ
  • Insert < 20 kb
  • Codon optimization for translation yield
  • Modified nucleosides, eg. M5C
  • Insert < 6 kb
  • Codon optimization for translation yield
  • Insert < 4 kb
UTR Regulatory elements in the 5’ and 3’-UTR stabilize mRNA and increase translation initiation Replicon for further self-replication of the mRNA Include IRES + PIE + other elements
PolyA tail Stabilizes RNA molecule & Prevents degradation Stabilizes RNA molecule & Prevents degradation Not required
Protein Expression +++ Strong +++++ Strongest ++++ Stronger
Expression half-life +++ Shorter +++++ Longest ++++ Longer
Immunogenicity ++++ Low ++ High +++ Medium
Dosage requirement ++ High +++++ Lowest +++ Medium
Novelty +++ Traditional ++++ Novel +++++ Novel


mRNA Case Study Report

Case studies showing high expression efficiency of GenScript’s mRNA for expressing SB transposase, GFP, Luciferase, eSpCas9, and more.

Free Download
Critical Consideration in Sourcing mRNA_Whitepaper
Critical Consideration in Sourcing mRNA_Whitepaper

This whitepaper provides valuable insights into the essential factors that vaccine and therapy developers should consider when exploring mRNA solutions

Free Download
Advancements in mRNA manufacturing_eBook
Advancements in mRNA manufacturing_eBook

Get GenScript’s free application eBook on therapeutics development with mRNA manufacturing solutions

Free Download
mRNA Therapy Modalities_Infographic
mRNA Therapy Modalities_Infographic

Learn about key structural features and functions of IVT mRNA and LNP, therapeutic modalities beyond prophylactic vaccines, mRNA candidates progressing through clinical trials.

Free Download
mRNA Parts_Infographic
mRNA Parts_Infographic

Learn about the main structural components of mRNA, the functional roles of each part, what constitutes high-quality IVT mRNA and more.

Free Download


Additional mRNA Offerings

Get in Touch
with GenScript IVT mRNA
Production Services

Get in Touch with GenScript Services
Please enter a valid first name.
Please enter a valid last name.
Please enter a valid email name.
Please select a valid industry.
Please select a valid country.
Please enter a valid Zipcode.
Please enter a valid institution/company.
Please enter a message in the textarea.



Do you like the current new website?